Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum 9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.

GREY:DGCRF - Post Discussion

9342-8530 Quebec Inc > CASH DISTRIBUTION SHOULD BE AT LEAST $0.25/SHARE
View:
Post by modulex on Dec 27, 2015 11:15am

CASH DISTRIBUTION SHOULD BE AT LEAST $0.25/SHARE

The Diagnocure-Hologic recent deal should have been long ago concluded. It took a ridiculous, wasting time for nothing to have it happened. Since Diagnocure had a significant business relationship with Gen-Probe, which was acquired by Hologic, Diagnocure was by all means entitled to know immediately upon the closing of the Hologic-Gen Probe acquisition what would go on forward with PCA3. Diagnocure made attempts in vain to sit down, hold talks with Hologic. Hologic has truly caused Diagnocure shareholders and its stock to be critically beaten-up as no action was taken. A multi-billion dollar company like Hologic is not corporately responsible when it fools around with a tiny company like Diagnocure. I dont know who is to be credited for having finally brought Hologic to put its act together and wake up but this/these person(s) deserves credit and thankfulness. Diagnocure shareholders should receive a cash distribution of at least $0.25/share as part of this deal for the troublesome behaviour displayed by Hologic in letting this matter go on for way too long delays. Since most of Diagnocure shares are held by canadian investors and the current value of the canadian dollar versus the american dollar, it would end up costing Hologic fairly cheap to pay $0.25/share to Diagnocure shareholders. $0.25 is also Diagnocure's current 52-weeks high, which therefore makes full sense to have Hologic to compensate Diagnocure shareholders to at least $0.25/share.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities